What does the evidence currently show Data from randomized controlled trials (RCTs) and meta-analysis of RCTs show that semaglutide and tirzepatide (two types of GLP-1 medications) reduce body weight, waist circumference, and improve major cardiometabolic risk biomarkers (e.g
Semaglutide produces meaningful liver fat reductions of approximately 40-55%, but nowhere near the magnitude seen with retatrutide
This expansion allows: Easier long-term adherence Alternative dosing options Greater comfort for maintenance phases Your provider will determine whether injections or pills are right for your tapering or maintenance plan
Hims & Hers Health announced plans to expand to Canada in 2026
Because it turns on three receptors at once, researchers use it to look at: Triple receptor (GLP-1 / GIP / glucagon) signaling Obesity and belly-fat models Appetite and food-intake studies Insulin sensitivity and blood-sugar control Energy burn (thermogenesis) through glucagon activation Heart and metabolic risk-factor studies Side-by-side tests with Tirzepatide and Semaglutide These uses come from published clinical and review research on this peptide and related incretin compounds
What Could Be the Main Challenges Associated with the Combination of SGLT2is and GLP1-RAs in Daily Clinical Practice